Fusion Antibodies gears up for flotation on the AIM

December 5, 2017

The Belfast Telegraph has reported that CoFund portfolio company Fusion Antibodies is set to list on the AIM market.

The Belfast Telegraph has reported that CoFund portfolio company Fusion Antibodies is set to list on the AIM market.

Share the Post:

Related Posts

(L-R) Liam McStravick, CEO & Co-Founder of TeamFeePay, Mike Clarke, Non-Executive Director at YFM Equity Partners, Stuart Gaffikin, Investment Director at Clarendon Fund Managers.

Clarendon Fund Managers Supports TeamFeePay’s UK and European Growth Ambitions

Clarendon Fund Managers is delighted to continue its support of TeamFeePay, following the company’s successful securing of new investment to accelerate growth across the UK and expand into European markets.

Audit Comply

Canadian investment marks new chapter for Belfast software firm AuditComply as Clarendon Fund Managers completes successful exit

Belfast-based compliance software developer AuditComply has been sold for an undisclosed sum to Toronto-headquartered cloud-based manufacturing software experts Nulogy, resulting in a successful exit for Co-Fund NI.